Alpha Tau Medical Ltd · NASDAQ:DRTS
Alpha Tau Medical — Investor Presentation (March 2026)
37 slides from Alpha Tau Medical's investor presentation, Mar 9, 2026
Slide 1: Investor Presentation
(NASDAQ:DRTS) Investor Presentation 1
Slide 2: Disclaimer
Disclaimer This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to Alpha Tau Medical Ltd. (“Alpha Tau” or the “Company”). By accepting this Present
Slide 3: Alpha Tau Overview
Alpha Tau Overview A novel approach using localized alpha particle radiotherapy designed to precisely destroy solid tumors while sparing surrounding healthy tissue Alpha DaRT Advantages Increasing Corporate Momentum Short-range radiation supporting safety + efficacy Multiple upcoming milestones in n
Slide 4: Anticipated Milestones
Anticipated Milestones Geography Target Indication H1 2026 H2 2026 Recurrent Complete multi-center Cutaneous SCC Data Readout + Potential FDA submission pivotal recruitment United Complete Recruitment Pancreatic Cancer Initial Readout from Pilot Study States in Pilot Study Recurrent Initial Safety R
Slide 5: Alpha Radiation is Focal - Short Range Limits Clinical Use
Alpha Radiation is Focal - Short Range Limits Clinical Use Whereas beta and gamma radiation can penetrate tissue with sufficient range to facilitate tumor coverage (while risking damage to healthy tissue), alpha radiation has short range in tissue (<100 μm), which limits its clinical usefulness in l
Slide 6: Alpha DaRT Technology is Designed to Overcome These Limitations
Alpha DaRT Technology is Designed to Overcome These Limitations 224Ra Decay Chain Alpha DaRT leverages the innate decay chain of Radium-224 The decay chain of Radium-224 includes four alpha particles Radium-224 has a half-life of ~3.7 days, while the remaining decay chain has a total half-life of ap
Slide 7: Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy
Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy https://www.youtube.com/watch?v=nwfzJHm0fTQ 7
Slide 8: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 9: Initial Foray into Superficial Tumors
Initial Foray into Superficial Tumors Alpha DaRT first tested in superficial tumors – tumors of the skin or head & neck, due to: • Ease of access • Straightforward control • Ongoing monitoring • Strong initial preclinical data in Squamous Cell Carcinoma (SCC) Treatment of hundreds of tumors to date:
Slide 10: U.S. Skin Cancer Pilot Study Leading to Pivotal Study
U.S. Skin Cancer Pilot Study Leading to Pivotal Study U.S. Pilot Feasibility Study Locations 5 centers – led by Memorial Sloan Kettering Cancer Center # of Patients 10 Treated Adverse Events 22 reported AE’s, most were mild or moderate No treatment-related serious AEs Pre Treatment Complete Response
Slide 11: Potential cSCC Patient Breakdown - Estimated U.S. Incidence
Potential cSCC Patient Breakdown - Estimated U.S. Incidence 1.8mm new U.S. cSCC incidences per year 1 ~419k high-risk cases (~23.3%) 2 Targeted population ~64k cases per year Targeted Population Estimated new U.S. cases per year of cSCC with local recurrence and/or nodal metastasis (3.5%)3 1 https:/
Slide 12: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 13: Case Study: Potential Systemic Immune Effect Observed in One cSCC Patient
Case Study: Potential Systemic Immune Effect Observed in One cSCC Patient Where a Second, Untreated Lesion Manifested CR Complete Response + Potential Systemic Immune Effect Treated Tumor Untreated Tumors Before After Before After 30-Nov-17 29-Dec-17 30-Nov-17 29-Dec-17 13
Slide 14: Outline of Checkpoint Inhibitor Combination Trial – CTP-HNCPI-00
Outline of Checkpoint Inhibitor Combination Trial – CTP-HNCPI-00 Key Eligibility Criteria Benchmark Comparator Recurrent unresectable or metastatic head and neck KEYNOTE-048: Benchmark comparator data for 1L Pembrolizumab in patients with recurrent or metastatic HNSCC1 squamous cell carcinoma (like
Slide 15: Early Interim Data Show Strong Systemic Responses
Early Interim Data Show Strong Systemic Responses • As of January 9, 2025, eight patients were treated with Alpha DaRT and pembrolizumab in the study • Baseline characteristics: • 3 female /5male • Mean ageof 73 years (range61-96) • 6mHNSCC /2laHNSCC • Patients received anaverage of 4 cycles of pemb
Slide 16: HNCPI-00-01-003 Pembrolizumab Combination Case Study
Confidential HNCPI-00-01-003 Pembrolizumab Combination Case Study 16
Slide 17: Case Background – HNCPI-00-01-003
Case Background – HNCPI-00-01-003 Age 96 Sex Female Tumor Type SCC Date of First Diagnosis Jul-2022 Location Alveolar ridge & lip plus dermal involvement Prior Treatments None Medical Background • Cardio • Dementia • ECOG3 Cancer Stage • Stage IV • T2N1M1 17
Slide 18: Alpha DaRT Treatment
Alpha DaRT Treatment Alpha DaRT After Alpha DaRT Follow-Up Insertion Removal Sept-2022 Oct-2022 Jan-2023 18
Slide 19: Clinical Follow-Up
Clinical Follow-Up Pre-Treatment Nine Weeks Post Treatment 19
Slide 20: Patient Status
Patient Status Patient stopped Pembrolizumab after 12 months Patient still alive with no evidence of disease at October 2024 followup 20
Slide 21: HNSCC Patient Breakdown
HNSCC Patient Breakdown 54,000 cases of HNSCC in US/year¹ 65% are or become R/M HNSCC² ~35,100 cases/year 42% R/M HNSCC patients receive 1L Keytruda treatment³ ~15,000 cases/year ¹Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma Adam Barsouk, John Sukumar Aluru, Pr
Slide 22: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 23: Focus on Internal Organ Treatments
Focus on Internal Organ Treatments We continue to make progress across internal organ programs, with trials underway in multiple targeted indications and others in various stages of planning and start-up Internal Organs in Focus • Pancreas – clinical trial underway • Liver – clinical trial underway
Slide 24: Interim Pancreatic Cancer Results - Overview of Trial Design
Interim Pancreatic Cancer Results - Overview of Trial Design Three trials treating pancreatic cancer patients in parallel: • CTP-PANC-101 monotherapy treatment at 2 sites in Montreal, Canada – up to 37 patients total • CTP-PANC-02 monotherapy treatment at 1 site in Jerusalem, Israel – up to 15 patie
Slide 25: High Disease Control Rate Observed
High Disease Control Rate Observed Among the 41 patients treated, 33 had a measured objective response, with 5 patients awaiting response evaluation and 3 who discontinued prior to evaluation. Results are presented below using Best Overall Response (BOR) for those with a measured response. Including
Slide 26: Highlights of Overall Survival (OS) Data
Highlights of Overall Survival (OS) Data Key Caveats: • The data are still relatively immature, but ongoing • Trial designs were focused on feasibility and safety, without the frequent monitoring visits common in studies focused on precise measurement of survival • Five patients treated since Nov 25
Slide 27: Analysis of Overall Survival in Key Sub-Populations (1/3)
Analysis of Overall Survival in Key Sub-Populations (1/3) Newly Diagnosed / Not Eligible for Chemotherapy (n=8) Product-Limit Survival Estimate With Number of Subjects at Risk 1.0 Censored 7.5 Median OS Since Diagnosis Without 0.8 4/8 Patients Still Alive Survival Probability Chemo (months) 0.6 3.5
Slide 28: Analysis of Overall Survival in Key Sub-Populations (2/3)
Analysis of Overall Survival in Key Sub-Populations (2/3) Metastatic (Stage IV) Patients After 1L FOLFIRINOX (n=10) Product-Limit Survival Estimate NR* With Number of Subjects at Risk 8 / 10 Patients Median OS Since Initiation of 1L 1.0 Censored Still Alive FOLFIRINOX (months) 11.1 10.8 0.8 10.1 Sur
Slide 29: Analysis of Overall Survival in Key Sub-Populations (3/3)
Analysis of Overall Survival in Key Sub-Populations (3/3) Progressed After 2L Gemcitabine-Abraxane (n=7) Product-Limit Survival Estimate With Number of Subjects at Risk 1.0 23.0 Censored Median OS Since Initiation of 2L 3 / 7 Patients Gemcitabine + Abraxane Still Alive 0.8 Survival Probability (mont
Slide 30: Pancreatic Cancer Clinical Trial: FDA Approval of IDE for U.S. Pilot
Pancreatic Cancer Clinical Trial: FDA Approval of IDE for U.S. Pilot N=15 1 Newly Diagnosed Primary Endpoint: Locally Advanced Insertion Incidence of Treatment- Pancreatic Cancer (During Cycles 1-4) Emergent Adverse Events 8-12 cycles of mFOLFIRINOX 2 Secondary Endpoints: N=15 Overall Survival Progr
Slide 31: Pancreatic Cancer: Massive and Growing Unmet Need
Pancreatic Cancer: Massive and Growing Unmet Need There are over half a million new cases of pancreatic cancer per year. Approx. 66k of them are in the U.S. Stage 1 Stage 2 Resectable Borderline 13% Resectable 10% Stage 3 Incidence rate of pancreatic Locally cancer is trending upward, Advanced U.S.
Slide 32: The Next Frontier: Glioblastoma Multiforme (GBM) / Brain Cancers
The Next Frontier: Glioblastoma Multiforme (GBM) / Brain Cancers GBM is one of the most complex, deadly, and treatment-resistant cancers, with estimated average survival of only 8 months¹. There is a high unmet need for a life extending treatment for GBM, with a mortality rate of 93% after 5 years¹
Slide 33: Therapeutic Focus
Therapeutic Focus We are focused on delivering solutions to three markets that we believe would be best served by the unique characteristics of the Alpha DaRT Localized & Unresectable Metastatic High Unmet Need • Localized tumors that are not • Alpha DaRT being evaluated for • Solid tumors that have
Slide 34: Global Manufacturing Facilities
Global Manufacturing Facilities For efficient commercial operations, we look to establish manufacturing operations in multiple regions of the world, to enable relatively short shipping times to our core markets. We are currently building our first commercial-scale facility in Hudson, NH Jerusalem (O
Slide 35: Anticipated Milestones
Anticipated Milestones Geography Target Indication H1 2026 H2 2026 Recurrent Complete multi-center Cutaneous SCC Data Readout + Potential FDA submission pivotal recruitment United Complete Recruitment Pancreatic Cancer Initial Readout from Pilot Study States in Pilot Study Recurrent Initial Safety R
Slide 36: Financial Position
Financial Position Public Since Mar-2022 (NASDAQ:DRTS) $76.9mm in Cash & Deposits at YE 2025 Well Financed for Execution 36
Slide 37: Saving Lives Globally
AlpheFAU Saving Lives Globally
Alpha Tau Medical — Investor Presentation (March 2026) on 6ix